Skip to main navigation
Skip to search
Skip to main content
Experts@Minnesota Home
Search content at Experts@Minnesota
Home
Profiles
Research units
University Assets
Projects and Grants
Research output
Datasets
Press/Media
Activities
Fellowships, Honors, and Prizes
Impacts
PI3K signaling pathway in normal B cells and indolent B-cell malignancies
Georgios Pongas
, Bruce D. Cheson
Research output
:
Contribution to journal
›
Review article
›
peer-review
34
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'PI3K signaling pathway in normal B cells and indolent B-cell malignancies'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Chronic Lymphocytic Leukemia
100%
B-cell Malignancies
100%
Kinase Cascade
100%
Phosphatidylinositol 3-kinase Inhibitor
100%
Phosphatidylinositol 3-kinase Signaling
100%
Normal B Cells
100%
Rituximab
66%
Autoimmune
33%
Leukemia-lymphoma
33%
Non-Hodgkin Lymphoma
33%
Chemoimmunotherapy
33%
U.S. Food
33%
Clinical Experience
33%
Indolent non-Hodgkin Lymphoma
33%
Follicular Lymphoma
33%
Small Lymphocytic Lymphoma
33%
Phosphatidylinositol 3-kinase Pathway
33%
Molecular Targeted Agents
33%
B-cell Receptor Signaling
33%
Lymphoma B-cell
33%
Idelalisib
33%
Medicine and Dentistry
B Cell
100%
Cancer
100%
Cell Signaling Pathway
100%
B-Cell Chronic Lymphocytic Leukemia
100%
Phosphoinositide 3-Kinase
100%
Kinase Signaling
100%
Phosphoinositide 3-Kinase Inhibitor
100%
Non-Hodgkin Lymphoma
66%
Rituximab
66%
Follicular Lymphoma
33%
Chemoimmunotherapy
33%
Lymphocytic Lymphoma
33%
B Lymphocyte Receptor
33%
Idelalisib
33%
Autoimmunity
33%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Lymphatic Leukemia
100%
Phosphatidylinositol 3 Kinase
100%
Phosphatidylinositol 3 Kinase Inhibitor
100%
Nonhodgkin Lymphoma
66%
Rituximab
66%
Lymphocytic Lymphoma
33%
B Lymphocyte Receptor
33%
Idelalisib
33%
Follicular Lymphoma
33%